Syngeneic Tumor Models with Resistance Mechanisms to PD-1 Blockade
PD-1 blockade has demonstrated remarkable clinical efficacy across various tumor types. However, primary or acquired resistance eventually leads to cancer...
Continue Reading
PD-1 blockade has demonstrated remarkable clinical efficacy across various tumor types. However, primary or acquired resistance eventually leads to cancer...
Continue Reading
The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...
Continue Reading
Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...
Continue Reading
Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term...
Continue Reading
SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...
Continue Reading
SITC Poster #452: Alopecia areata (AA) is an autoimmune disease characterized by patchy and sudden hair loss without scarring, resulting...
Continue Reading
SITC Poster #446: Inflammatory bowel disease (IBD) is recognized as an autoimmune disorder characterized by chronic inflammation of the digestive...
Continue Reading
SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant...
Continue Reading
At the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...
Continue Reading